

Long acting reversible contraception recommendation rates at a sexual health clinic



Dimitrov-Zeller S¹, Brooker C², Donaghy E², Creagh A²

¹Fiona Stanley Hospital, Perth, Western Australia ²Sexual Health Quarters, Perth, Western Australia

s.dimitrov-zeller@hotmail.com

Introduction

- Long acting reversible contraception (LARC) refers to intrauterine levonorgestrel and copper containing contraceptive devices, and contraceptive implants.1
- LARCs have many advantages including but not limited to: being the most effective reversible contraceptive methods, cost-effectiveness and very few contraindications.1
- Despite the many benefits, LARC uptake in Australia is relatively low.1
- The RANZCOG recommends offering LARCs as a first line contraceptive method.1
- We aimed to assess the proportion of patients recommended a LARC in our audit population.





Methods

- Date range of 1st July to 31st August 2019 inclusive was selected
- Patients, none of whom had contraindications to all LARCs, who attended a contraception appointment at the sexual health clinic were Figure: Documented LARC retrospectively audited using electronic records
- Patients already using a LARC and repeat attendees within the time period were excluded
- 70 patients selected for audit

Results

- 30 of 70 patients (42.9%) were documented as being offered a LARC during the audit period.
- Of the 40 patients who were not documented as being offered a LARC:

recommendation rates

37.1%

Offered (audi

period) 42.9%

- > 32 (80%) had been seen in the previous 12 months
 - 14 of 32 (43.8%) of these patients were documented as being offered a LARC in the preceding 12 months; (i.e. 44 of total 70 (62.9%) in 12 months)
- > 17 (42.5%) were currently using medroxyprogesterone injection as contraception

Discussion

- Results highlight that the proportion of patients documented as being offered a LARC may be improved.
- During follow up appointments, clinicians seem less likely to offer LARCs. Though many patients were already using a method of contraception with high satisfaction such as medroxyprogesterone injection, which is considered by some authors to be a LARC.
- Given the significant advantages of LARCs, clinicians should endeavour to offer them, and address barriers to uptake.

Reference

1. The Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Long acting reversible contraception C-Gyn 34 guideline. Jul 2017.